New Study Reveals Brain Circuit Biomarkers to Predict Response to Treatment in Patients with Complex Neuropsychiatric Disorders

Cohen Veterans Bioscience (CVB), a non-profit research biotech advancing brain health solutions, today announces findings from a study which generates new evidence in support of a critical brain imaging biomarker, that may help guide people who suffer from post-traumatic stress disorder (PTSD) or major depressive disorder (MDD) towards the most effective treatment.

The study, entitled “Identification of psychiatric disorder subtypes from functional connectivity patterns in resting-state electroencephalography (EEG)” was led by Stanford University professor of psychiatry and behavioral sciences, Amit Etkin, MD, PhD, and received major funding from CVB.

In the findings, reported in the journal Nature Biomedical Engineering, the authors used advanced machine learning techniques on data from high density resting-state EEG signals to identify robust and distinct functional connectivity patterns in brain circuits enabling subtyping of patients, independent of clinical diagnosis.